August 8, 2018
Our manufacturing partner Meridian Medical Technologies, a Pfizer company, continues to experience interruptions in the production of EpiPen® (epinephrine injection, USP) 0.3 mg and EpiPen Jr® (epinephrine injection, USP) 0.15 mg Auto-Injectors. Over the past few months, there has been intermittent supply of EpiPen at wholesalers and pharmacies. We are actively exploring several options with Pfizer that would help stabilize supply. We will continue to provide updates, including timing for resolution, as we receive them from Pfizer.
Pfizer's statement is available here.
We appreciate how important it is for individuals with life-threatening allergies to have access to epinephrine auto-injectors, and understand the challenges this situation continues to pose for patients. Pfizer is working hard to increase production and stabilize supplies, but until this occurs, supplies of EpiPen® 0.3 mg and EpiPen Jr® 0.15 mg Auto-Injectors, and the authorized generic versions of these strengths, will continue to vary from pharmacy to pharmacy and may not always be available.
Our priority is to ensure patients with a life-threatening allergy have access to epinephrine auto-injector products. For our part, we are expediting shipments upon receipt from Pfizer. We also are working closely with Pfizer to stay informed of anticipated shipments and are maintaining regular dialogue with health authorities to provide frequent updates on supply status.
We continue to encourage patients to call our Mylan Customer Relations at 800-796-9526 for assistance in locating alternative pharmacies. The team has successfully located product for patients who are experiencing difficulty accessing their prescription. To further assist patients during this period of limited supply, we recently extended our Customer Relations hours to Monday through Friday, 8 a.m. to 7 p.m. ET.
To support patient access to the product during this supply constraint, we are encouraging healthcare professionals to manage prescription renewals diligently.